Printer Friendly

Bioverativ reports Q3 adjusted EPS 80c, consensus 69c.

Reports Q3 revenue $291.6M, consensus $285.49M. "We are pleased with the progress of the business in the quarter as we continued to deliver on all of our priorities. Our hemophilia franchise grew thanks to strong commercial execution and differentiation of our leading extended half-life products, ELOCTATE and ALPROLIX," said John Cox, Chief Executive Officer of Bioverativ. "We made significant progress advancing our pipeline with the initiation of the Phase 1/2a trial for BIVV001 and the FDA's acceptance of an IND application for ST-400, a gene-edited cell therapy candidate to treat beta-thalassemia being developed in collaboration with Sangamo Therapeutics. We also entered into a strategic research collaboration with Bicycle Therapeutics to develop innovative therapies to treat rare blood disorders."

COPYRIGHT 2017 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Article Type:Financial report
Date:Oct 26, 2017
Previous CEO says Alexa experience will get even better.
Next Article:ADP announces letter to stockholders urging vote for company director nominees.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters